Mesenchymal stem cells and organ transplantation: Initial clinical results

Antonello Pileggi, Xiumin Xu, Jianming Tan, Camillo Ricordi

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

The widespread application of organ transplantation to the large population of patients with end-stage organ failure who are in dire need of its benefits is currently being hampered by a number of challenges. Amongst them are the shortage of organs for transplantation and the need for lie-long immunosuppression with the associated untoward side effects. The field of regenerative medicine is rapidly evolving, thus creating exciting opportunities toward the development of novel therapeutic protocols aimed at ameliorating, reducing, modifying, correcting and curing medical conditions. Mesenchymal stromal (stem) cells (MSCs) are appealing for inclusion in organ transplantation protocols because of the increasing body of evidence in support of their beneficial properties both in tissue repair and for the modulation of immunity. Herein, we review the encouraging results of the recent clinical trials on the use of MSCs in organ transplantation.

Original languageEnglish (US)
Title of host publicationStem Cell-Dependent Therapies: Mesenchymal Stem Cells in Chronic Inflammatory Disorders
PublisherWalter de Gruyter GmbH
Pages143-162
Number of pages20
ISBN (Electronic)9783110298307
ISBN (Print)9783110298260
DOIs
StatePublished - Jan 1 2013

Fingerprint

Mesenchymal Stem Cell Transplantation
Transplantation (surgical)
Organ Transplantation
Stem cells
Mesenchymal Stromal Cells
Regenerative Medicine
Curing
Repair
Modulation
Immunosuppression
Tissue
Immunity
Clinical Trials
Population

ASJC Scopus subject areas

  • Medicine(all)
  • Biochemistry, Genetics and Molecular Biology(all)
  • Immunology and Microbiology(all)

Cite this

Pileggi, A., Xu, X., Tan, J., & Ricordi, C. (2013). Mesenchymal stem cells and organ transplantation: Initial clinical results. In Stem Cell-Dependent Therapies: Mesenchymal Stem Cells in Chronic Inflammatory Disorders (pp. 143-162). Walter de Gruyter GmbH. https://doi.org/10.1515/9783110298307.143

Mesenchymal stem cells and organ transplantation : Initial clinical results. / Pileggi, Antonello; Xu, Xiumin; Tan, Jianming; Ricordi, Camillo.

Stem Cell-Dependent Therapies: Mesenchymal Stem Cells in Chronic Inflammatory Disorders. Walter de Gruyter GmbH, 2013. p. 143-162.

Research output: Chapter in Book/Report/Conference proceedingChapter

Pileggi, A, Xu, X, Tan, J & Ricordi, C 2013, Mesenchymal stem cells and organ transplantation: Initial clinical results. in Stem Cell-Dependent Therapies: Mesenchymal Stem Cells in Chronic Inflammatory Disorders. Walter de Gruyter GmbH, pp. 143-162. https://doi.org/10.1515/9783110298307.143
Pileggi A, Xu X, Tan J, Ricordi C. Mesenchymal stem cells and organ transplantation: Initial clinical results. In Stem Cell-Dependent Therapies: Mesenchymal Stem Cells in Chronic Inflammatory Disorders. Walter de Gruyter GmbH. 2013. p. 143-162 https://doi.org/10.1515/9783110298307.143
Pileggi, Antonello ; Xu, Xiumin ; Tan, Jianming ; Ricordi, Camillo. / Mesenchymal stem cells and organ transplantation : Initial clinical results. Stem Cell-Dependent Therapies: Mesenchymal Stem Cells in Chronic Inflammatory Disorders. Walter de Gruyter GmbH, 2013. pp. 143-162
@inbook{dbfcc317c18f49c8be43b5e07d7ee44d,
title = "Mesenchymal stem cells and organ transplantation: Initial clinical results",
abstract = "The widespread application of organ transplantation to the large population of patients with end-stage organ failure who are in dire need of its benefits is currently being hampered by a number of challenges. Amongst them are the shortage of organs for transplantation and the need for lie-long immunosuppression with the associated untoward side effects. The field of regenerative medicine is rapidly evolving, thus creating exciting opportunities toward the development of novel therapeutic protocols aimed at ameliorating, reducing, modifying, correcting and curing medical conditions. Mesenchymal stromal (stem) cells (MSCs) are appealing for inclusion in organ transplantation protocols because of the increasing body of evidence in support of their beneficial properties both in tissue repair and for the modulation of immunity. Herein, we review the encouraging results of the recent clinical trials on the use of MSCs in organ transplantation.",
author = "Antonello Pileggi and Xiumin Xu and Jianming Tan and Camillo Ricordi",
year = "2013",
month = "1",
day = "1",
doi = "10.1515/9783110298307.143",
language = "English (US)",
isbn = "9783110298260",
pages = "143--162",
booktitle = "Stem Cell-Dependent Therapies: Mesenchymal Stem Cells in Chronic Inflammatory Disorders",
publisher = "Walter de Gruyter GmbH",
address = "Germany",

}

TY - CHAP

T1 - Mesenchymal stem cells and organ transplantation

T2 - Initial clinical results

AU - Pileggi, Antonello

AU - Xu, Xiumin

AU - Tan, Jianming

AU - Ricordi, Camillo

PY - 2013/1/1

Y1 - 2013/1/1

N2 - The widespread application of organ transplantation to the large population of patients with end-stage organ failure who are in dire need of its benefits is currently being hampered by a number of challenges. Amongst them are the shortage of organs for transplantation and the need for lie-long immunosuppression with the associated untoward side effects. The field of regenerative medicine is rapidly evolving, thus creating exciting opportunities toward the development of novel therapeutic protocols aimed at ameliorating, reducing, modifying, correcting and curing medical conditions. Mesenchymal stromal (stem) cells (MSCs) are appealing for inclusion in organ transplantation protocols because of the increasing body of evidence in support of their beneficial properties both in tissue repair and for the modulation of immunity. Herein, we review the encouraging results of the recent clinical trials on the use of MSCs in organ transplantation.

AB - The widespread application of organ transplantation to the large population of patients with end-stage organ failure who are in dire need of its benefits is currently being hampered by a number of challenges. Amongst them are the shortage of organs for transplantation and the need for lie-long immunosuppression with the associated untoward side effects. The field of regenerative medicine is rapidly evolving, thus creating exciting opportunities toward the development of novel therapeutic protocols aimed at ameliorating, reducing, modifying, correcting and curing medical conditions. Mesenchymal stromal (stem) cells (MSCs) are appealing for inclusion in organ transplantation protocols because of the increasing body of evidence in support of their beneficial properties both in tissue repair and for the modulation of immunity. Herein, we review the encouraging results of the recent clinical trials on the use of MSCs in organ transplantation.

UR - http://www.scopus.com/inward/record.url?scp=84979167695&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84979167695&partnerID=8YFLogxK

U2 - 10.1515/9783110298307.143

DO - 10.1515/9783110298307.143

M3 - Chapter

AN - SCOPUS:84979167695

SN - 9783110298260

SP - 143

EP - 162

BT - Stem Cell-Dependent Therapies: Mesenchymal Stem Cells in Chronic Inflammatory Disorders

PB - Walter de Gruyter GmbH

ER -